CTOs on the Move

MSI

www.methylationsciences.com

 
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

MSI raised $30M on 10/07/2016

Similar Companies

Petvisor

Petvisor is a company that delivers a suite of mobile-enabled technologies to pet care professionals, helping them care for pet families. They provide tools to engage customers, streamline operations, and grow businesses in the veterinary health and pe...

Doheny Eye Institute

Doheny Eye Institute is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Doheny Eye Institute is based in Los Angeles, CA. You can find more information on Doheny Eye Institute at www.doheny.org

Welch Healthcare and Retirement

Welch Healthcare and Retirement is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Campanile Plastic Surgery

Campanile Plastic Surgery is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hansei Solutions

To be Hansei is to reflect on the past, learn from mistakes, and commit to doing better in the future. To stop Hansei is to stop learning. Hansei Solutions helps behavioral healthcare facilities nationwide do it better, combining full-service revenue cycle management technology with a personal touch to forge lasting and strategic partnerships. Simply put, Hansei enables providers to collect more, save more, remain compliant, and make more informed decisions impacting their growth and bottom line.